Body Fluids-Based Diagnostics to Be Developed and Validated

The Gen 3 tests will focus on cardiovascular indications, neurodegenerative diseases, women's health, and early detection of certain cancers, and are designed to leverage microRNA biomarkers extracted from body fluids.

A leading developer and provider of microRNA-based molecular diagnostics, Rosetta Genomics (Rehovot, Israel) has entered into agreements with Tel Hashomer Medical Research Infrastructure and Services Ltd (Tel Aviv, Israel) and Carmel Medical Center (Haifa, Israel).

The collaborations are an integral part of Rosetta Genomics' Gen 3 product development process as they utilize the capabilities and samples at these specialized centers to identify initial microRNA candidate biomarkers for the company's discovery-stage projects.

MicroRNAs (miRNAs) are small RNAs that act as master regulators of protein synthesis, and have been shown to be highly effective biomarkers. The unique advantage of microRNAs as biomarkers lies in their high tissue specificity, and their exceptional stability in the most routine preservation methods for biopsies, including Formalin Fixed Paraffin Embedded (FFPE) block tissue and fine needle aspirate (FNA) cell blocks.

"One of Rosetta Genomics' core strengths is our ability to rapidly advance high-value diagnostics through our development engine. Toward that end, we have made significant scientific and technological advances that allow us to optimize the extraction of microRNAs from various body fluids. We are using these capabilities to advance the development of our first body fluids-based tests, which are also our first line of tests outside of oncology," said Kenneth A. Berlin, president and CEO of Rosetta Genomics.

Related Links:
Rosetta Genomics
Tel Hashomer Medical Research Infrastructure and Services Ltd.
Carmel Medical Center